<abstract xmlns="http://www.w3.org/1999/xhtml">

<sec><h3>Background</h3>
<p>The aim of the study was to report on the experience in a single tertiary cancer center about the treatment and outcome of patients with Graves’ disease (GD) and metastatic thyroid cancer as compared with patients without GD in our country.</p>
</sec>
<sec><h3>Patients and methods</h3>
<p>Altogether, 28 patients (8 males, 20 females; 49–85 years of age; median 74 years) were treated because of differentiated thyroid cancer and distant metastasis at the time of diagnosis during a 10-year period (from 2010 to 2019) in the Republic of Slovenia. The subject of our retrospective study were four patients (three men, one female; 64–76 years of age, median 73 years) who had Graves’ disease and metastatic thyroid cancer.</p>
</sec>
<sec><h3>Results</h3>
<p>The mean age of patients without GD and with GD was 74 years and 71 years, respectively (p = 0.36). There was a trend for male predominance in patients with GD (p = 0.06). There was no statistical difference in size of primary tumors, pT stage or pN stage between the group of patients without GD and with GD. The median length of follow-up was 3.33 years (range 0.04–7.83) and 5-year disease-specific survival was 51%. One of four patients with GD and 14 of 24 patients without GD died of thyroid cancer. There was no statistical difference in disease-specific survival between patients’ group of without GD and with GD (p = 0.59).</p>
</sec>
<sec><h3>Conclusions</h3>
<p>In our country Slovenia, 14% of patients with metastatic differentiated thyroid carcinoma at the time of diagnosis had Graves’ disease. There was no difference in the treatment, outcome or survival of patients with GD in comparison to those without GD.</p>
</sec>
</abstract>

Background
The aim of the study was to report on the experience in a single tertiary cancer center about the treatment and outcome of patients with Graves’ disease (GD) and metastatic thyroid cancer as compared with patients without GD in our country.

Patients and methods
Altogether, 28 patients (8 males, 20 females; 49–85 years of age; median 74 years) were treated because of differentiated thyroid cancer and distant metastasis at the time of diagnosis during a 10-year period (from 2010 to 2019) in the Republic of Slovenia. The subject of our retrospective study were four patients (three men, one female; 64–76 years of age, median 73 years) who had Graves’ disease and metastatic thyroid cancer.

Results
The mean age of patients without GD and with GD was 74 years and 71 years, respectively (p = 0.36). There was a trend for male predominance in patients with GD (p = 0.06). There was no statistical difference in size of primary tumors, pT stage or pN stage between the group of patients without GD and with GD. The median length of follow-up was 3.33 years (range 0.04–7.83) and 5-year disease-specific survival was 51%. One of four patients with GD and 14 of 24 patients without GD died of thyroid cancer. There was no statistical difference in disease-specific survival between patients’ group of without GD and with GD (p = 0.59).

Conclusions
In our country Slovenia, 14% of patients with metastatic differentiated thyroid carcinoma at the time of diagnosis had Graves’ disease. There was no difference in the treatment, outcome or survival of patients with GD in comparison to those without GD.

Treatment and outcome of patients with Graves’ disease and metastatic differentiated thyroid cancer

Radiology and Oncology

This work is licensed under the Creative Commons Attribution 4.0 International License.

Background
The aim of the study was to report on the experience in a single tertiary cancer center about the treatment and outcome of patients with Graves’...

Treatment and outcome of patients with Graves’ disease and metastatic differentiated thyroid cancer

Article Category: Research Article

Publié en ligne: 04 sept. 2023

Pages: 380 - 388

Reçu: 21 mars 2023

Accepté: 19 juin 2023

DOI: https://doi.org/10.2478/raon-2023-0034

Mots clés
differentiated thyroid cancer, metastases, Graves’ disease, treatment

© 2023 Nikola Besic et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Treatment and outcome of patients with Graves’ disease and metastatic differentiated thyroid cancer

Article Category: Research Article

Publié en ligne: 04 sept. 2023

Pages: 380 - 388

Reçu: 21 mars 2023

Accepté: 19 juin 2023

DOI: https://doi.org/10.2478/raon-2023-0034

Mots clésdifferentiated thyroid cancer, metastases, Graves’ disease, treatment

© 2023 Nikola Besic et al., published by Sciendo

This work is licensed under the Creative Commons Attribution 4.0 International License.

Mots clés
differentiated thyroid cancer, metastases, Graves’ disease, treatment